Relmada Therapeutics, Inc. RLMD Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueNewIssues.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment?
- Relmada Therapeutics, Inc. (RLMD) reported issuance of common stock in connection with the spin-off and reclassification of net parent investment of $150.38M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment changed year-over-year?
- Relmada Therapeutics, Inc.'s issuance of common stock in connection with the spin-off and reclassification of net parent investment increased by 542.4% year-over-year, from $23.41M to $150.38M.
- What does issuance of common stock in connection with the spin-off and reclassification of net parent investment mean?
- The total value of new common stock issued by the company to raise capital or fund operations. This metric highlights the company's reliance on equity financing to support its business activities and growth initiatives.